Catalog #BE0307

InVivoMAb anti-mouse CD16/CD32

Clone 2.4G2
Reactivities Mouse
Applications in vivo Fc receptor blocking
Fc receptor blocking
Flow cytometry
Immunofluorescence
Isotype Rat IgG2b, κ

$178.00 - $4,841.50

$178.00 - $4.00

Choose an Option...
  • 100 mg - $4,841.50
  • 50 mg - $3,464.00
  • 25 mg - $2,349.50
  • 5 mg - $688.50
  • 1 mg - $178.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left
US Customers - Order by Noon EST on Monday to receive by November 24.

Product Description

The 2.4G2 monoclonal antibody reacts specifically with mouse CD16 (FcγRIII) and CD32 (FcγRII). It has also been reported to react non-specifically via its Fc domain to FcγRI. CD16 and CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. These receptors bind to the Fc portion of antibody-antigen complexes and play a role in adaptive immune responses. The 2.4G2 antibody is commonly used in flow cytometry and immunofluorescence staining experiments to prevent non-specific binding of the Fc portion of IgG to the FcγIII and FcγII, and possibly FcγI, receptors prior to staining with antigen specific primary antibodies. The complete antibody and Fab fragments of the 2.4G2 antibody have also been used to block Fc receptors in vivo. Note that when 2.4G2 is used for Fc blocking in immunoassays and an anti-IgG secondary-step is necessary, the secondary antibody must not be anti-rat IgG2b.

Specifications

Isotype Rat IgG2b, κ
Recommended Isotype Control(s) InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin
Recommended Dilution Buffer InVivoPure pH 8.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Immunogen BALB/c mouse macrophage cell line J774
Reported Applications in vivo Fc receptor blocking
Fc receptor blocking
Flow cytometry
Immunofluorescence
Formulation PBS, pH 8.0
Contains no stabilizers or preservatives
Endotoxin ≤1EU/mg (≤0.001EU/μg)
Determined by LAL assay
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein G
RRID AB_2736987
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options

Application References

  • Fc receptor blocking Flow Cytometry
    Pasqual, G., et al (2018). "Monitoring T cell-dendritic cell interactions in vivo by intercellular enzymatic labelling" Nature 553(7689): 496-500.

    Interactions between different cell types are essential for multiple biological processes, including immunity, embryonic development and neuronal signalling. Although the dynamics of cell-cell interactions can be monitored in vivo by intravital microscopy, this approach does not provide any information on the receptors and ligands involved or enable the isolation of interacting cells for downstream analysis. Here we describe a complementary approach that uses bacterial sortase A-mediated cell labelling across synapses of immune cells to identify receptor-ligand interactions between cells in living mice, by generating a signal that can subsequently be detected ex vivo by flow cytometry. We call this approach for the labelling of ‘kiss-and-run’ interactions between immune cells ‘Labelling Immune Partnerships by SorTagging Intercellular Contacts’ (LIPSTIC). Using LIPSTIC, we show that interactions between dendritic cells and CD4(+) T cells during T-cell priming in vivo occur in two distinct modalities: an early, cognate stage, during which CD40-CD40L interactions occur specifically between T cells and antigen-loaded dendritic cells; and a later, non-cognate stage during which these interactions no longer require prior engagement of the T-cell receptor. Therefore, LIPSTIC enables the direct measurement of dynamic cell-cell interactions both in vitro and in vivo. Given its flexibility for use with different receptor-ligand pairs and a range of detectable labels, we expect that this approach will be of use to any field of biology requiring quantification of intercellular communication.

  • Fc receptor blocking Flow Cytometry
    Arbelaez, C. A., et al (2015). "IL-7/IL-7 Receptor Signaling Differentially Affects Effector CD4+ T Cell Subsets Involved in Experimental Autoimmune Encephalomyelitis" J Immunol 195(5): 1974-1983.

    IL-17-producing CD4(+) T (Th17) cells, along with IFN-gamma-expressing Th1 cells, represent two major pathogenic T cell subsets in experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS). The cytokines and transcription factors involved in the development and effector functions of Th1 and Th17 cells have been largely characterized. Among them, IL-23 is essential for the generation of stable and encephalitogenic Th17 cells and for the development of EAE. The IL-7/IL-7R signaling axis participates in cell survival, and perturbation of this pathway has been associated with enhanced susceptibility to MS. A link between IL-23-driven pathogenic T cells and IL-7/IL-7R signaling has previously been proposed, but has not been formally addressed. In the current study, we showed that Th17 cells from mice with EAE express high levels of IL-7Ralpha compared with Th1 cells. Using mice that constitutively express IL-7Ralpha on T cells, we determined that sustained IL-7R expression in IL-23R-deficient mice could not drive pathogenic T cells and the development of EAE. IL-7 inhibited the differentiation of Th17 cells, but promoted IFN-gamma and GM-CSF secretion in vitro. In vivo IL-7/anti-IL-7 mAb complexes selectively expanded and enhanced the proliferation of CXCR3-expressing Th1 cells, but did not impact Th17 cells and EAE development in wild-type and IL-23R-deficient mice. Importantly, high IL-7 expression was detected in the CNS during EAE and could drive the plasticity of Th17 cells to IFN-gamma-producing T cells. Together, these data address the contribution of IL-23/IL-23R and IL-7/IL-7R signaling in Th17 and Th1 cell dynamics during CNS autoimmunity.

  • Fc receptor blocking Flow Cytometry
    Liu, X., et al (2015). "CD47 blockade triggers T cell-mediated destruction of immunogenic tumors" Nat Med 21(10): 1209-1215.

    Macrophage phagocytosis of tumor cells mediated by CD47-specific blocking antibodies has been proposed to be the major effector mechanism in xenograft models. Here, using syngeneic immunocompetent mouse tumor models, we reveal that the therapeutic effects of CD47 blockade depend on dendritic cell but not macrophage cross-priming of T cell responses. The therapeutic effects of anti-CD47 antibody therapy were abrogated in T cell-deficient mice. In addition, the antitumor effects of CD47 blockade required expression of the cytosolic DNA sensor STING, but neither MyD88 nor TRIF, in CD11c(+) cells, suggesting that cytosolic sensing of DNA from tumor cells is enhanced by anti-CD47 treatment, further bridging the innate and adaptive responses. Notably, the timing of administration of standard chemotherapy markedly impacted the induction of antitumor T cell responses by CD47 blockade. Together, our findings indicate that CD47 blockade drives T cell-mediated elimination of immunogenic tumors.

  • Fc receptor blocking Flow Cytometry
    Peske, J. D., et al (2015). "Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity" Nat Commun 6: 7114.

    The presence of lymph node (LN)-like vasculature in tumours, characterized by expression of peripheral node addressin and chemokine CCL21, is correlated with T-cell infiltration and positive prognosis in breast cancer and melanoma patients. However, mechanisms controlling the development of LN-like vasculature and how it might contribute to a beneficial outcome for cancer patients are unknown. Here we demonstrate that LN-like vasculature is present in murine models of melanoma and lung carcinoma. It enables infiltration by naive T cells that significantly delay tumour outgrowth after intratumoral activation. Development of this vasculature is controlled by a mechanism involving effector CD8 T cells and NK cells that secrete LTalpha3 and IFNgamma. LN-like vasculature is also associated with organized aggregates of B lymphocytes and gp38(+) fibroblasts, which resemble tertiary lymphoid organs that develop in models of chronic inflammation. These results establish LN-like vasculature as both a consequence of and key contributor to anti-tumour immunity.

Product Citations

  • CD47 fuels intestinal fibrosis by inducing fibroblast phagocytic evasion and represents a therapeutic target.

    In Cell Rep Med on 20 October 2026 by Zhao, X., Wang, Y., et al.

    PubMed

    Intestinal fibrosis is a major complication of Crohn's disease, for which targeted therapies remain unavailable. Fibrosis is defined by excess matrix deposition, which may result from inadequate phagocytic clearance, yet how phagocytosis shifts here is unclear. Using single-cell and spatial transcriptomics, we identify fibrosis-associated CD47hi fibroblasts coupled to SIRPAhi macrophages in fibrotic regions. Cell-cell communication analyses and neutralizing-antibody experiments identify interleukin-1β as a mediator of their crosstalk, forming a profibrotic niche characterized by phagocytic evasion. Genetic disruption of fibroblast Cd47 or macrophage Sirpa enhances fibroblast clearance and attenuates fibrosis. Mechanistically, checkpoint disruption reprograms macrophages toward an NRF2-associated pro-phagocytic state, linking enhanced clearance to the antifibrotic response. Furthermore, therapeutic antibody blockade of this checkpoint attenuates intestinal fibrosis in mouse models with schedule-dependent efficacy. Collectively, these findings support CD47-mediated phagocytic evasion as a key pathogenic mechanism in intestinal fibrosis and identify CD47-SIRPα blockade as a promising therapeutic target.

  • Mucosal BCG vaccination reprograms lung interstitial macrophages and enhances antimicrobial defense in mice.

    In Mucosal Immunol on 1 October 2026 by Forde, A. J., Esposito, M., et al.

    PubMed

    Bacille Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB) but provides inconsistent protection against disease. Alveolar macrophages (AM) are widely considered the primary myeloid mediators of BCG-induced lung immunity, whereas the contribution of lung interstitial macrophages (IM) remains poorly defined. Here, we investigated pulmonary macrophage remodeling following BCG vaccination delivered by three distinct routes in mice, using flow cytometry, single cell RNA sequencing and spatial transcriptomics. We show that the route of vaccine administration dictates which macrophage subset is rewired. Intratracheal (IT) BCG preferentially reprograms IM, which form spatially organized immune hubs with CD4 T cells, while AM retain a transcriptional state closer to homeostasis. In contrast, intravenous (IV) BCG induces transcriptional remodeling of AM. Importantly, IT BCG conferred superior protection against both Mycobacterium tuberculosis and the heterologous pathogen Pseudomonas aeruginosa. Collectively, these findings identify IM as key mediators of mucosal vaccine-induced protection and highlight macrophage subset targeting as a framework for optimizing vaccines against respiratory pathogens.

  • ATF7 drives diabetic wound healing via NOTCH1 repression and N1ICD-dependent macrophage polarization control.

    In JCI Insight on 24 August 2026 by Xu, P., Xue, Y., et al.

    PubMed

    Chronic, non-healing wounds are a severe diabetic complication. The underlying mechanisms are not fully understood, and the role of ATF7 in this context has not been well characterized. In our study, we utilized db/db diabetic mice and AAV-mediated keratinocyte-specific Atf7 overexpression in vivo. HaCaT keratinocyte/THP-1 macrophage cocultures under high glucose were used in vitro. Our results showed that ATF7 was upregulated in diabetic wounds. Keratinocyte-specific Atf7 overexpression accelerated diabetic wound closure, enhanced re-epithelialization, granulation tissue formation, and keratinocyte proliferation, while suppressing macrophage M1 polarization and inflammation. Multiomics screening identified NOTCH1 as a key ATF7 target. ATF7 transcriptionally repressed NOTCH1 by recruiting Suv39h1, increasing H3K9me3 at the NOTCH1 promoter. This reduced NOTCH1 protein and its active intracellular domain (N1ICD) within keratinocyte-derived exosomes. ATF7-overexpressing keratinocyte exosomes carried less N1ICD, leading to decreased N1ICD transfer to macrophages and subsequent inhibition of M1 polarization. Notably, local injection of exosomes from ATF7-overexpressing keratinocytes accelerated wound healing in db/db mice. In summary, ATF7 promotes diabetic wound healing by repressing NOTCH1 transcription via H3K9me3, thereby reducing exosomal N1ICD secretion from keratinocytes and inhibiting macrophage M1 polarization. This identifies the ATF7/NOTCH1/exosome axis as a therapeutic target.

  • Microbial and metabolic signatures of humanized microbiome mice associate with Tlr2 expression and Th17 immune programming.

    In Front Immunol on 22 August 2026 by Cox-Holmes, A. N., Green, G. B. H., et al.

    PubMed

    The gut microbiota plays a critical role in immune system development. However, whether normal variation in healthy human microbiota alone can establish distinct baseline immune states that influences responses to disease and therapy remains unclear.

Product FAQs

Related Products

  1. Catalog #CP025
    RecombiMAb anti-mouse CD16/CD32 Read more
  2. Catalog #CP026
    RecombiMAb anti-mouse CD16/CD32 (LALA-PG) Read more

Additional Formats

  1. Catalog #BP0307
    InVivoPlus anti-mouse CD16/CD32 Read more
  2. Catalog #CP025
    RecombiMAb anti-mouse CD16/CD32 Read more
  3. Catalog #CP026
    RecombiMAb anti-mouse CD16/CD32 (LALA-PG) Read more